Please assess the completion status of the following clinical trial:

Trial Title: Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identification as a transgender individual \[As determined by the two-step process of gender identification whereby potential participants will be asked their gender identity and sex assigned at birth\]~* HIV-uninfected by EIA and viral load within 7 days of study entry~* Creatinine clearance ≥ 60 mL/min by Cockroft Gault for ages ≥18 years (Schwartz equation for those \<18)~* Willing to comply with all study procedures~* On a stable dose of cs-HT for at least 2 months verified by clinical chart review and willing to not change doses for duration of PK study~Exclusion Criteria:~* Hospitalization within 30 days of study entry (elective procedures okay with team approval)~* Condition (medical, psychological, or social) that, in the opinion of the study investigators, would preclude the participant from completing study-required procedures~* Previous participation in an HIV vaccine study, unless the participant can document placebo arm assignment~* Use of TDF/FTC in the past 3 months

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- TDF/FTC and cs-HT (Type: EXPERIMENTAL): Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.

Based on this trial design, predict the completion outcome and termination type (if applicable).